The purpose of this study is to provide men and women with relapsed/refractory multiple myeloma (RRMM) expanded access to the antibody-drug conjugate belantamab mafodotin.
This study is open to those who are either enrolled in the BLENREP REMS (Risk Evaluation and Mitigation Strategy) program, or who have RRMM refractory to immunomodulators (IMID), proteasome inhibitors (PI), and an anti-CD38 antibody, and no suitable alternative treatment options.
Belantamab mafodotin is considered investigational which means it is not yet approved by the U.S. Food and Drug Adminstration (FDA).
Participants will receive belantamab mafodotin intravenously (through a needle in the vein) over at least 30 minutes once every three weeks.
Participation in this research will last as long as participants continue to benefit.
Detailed eligibility will be reviewed when you contact the study team.